Sparks commentary - Newron Pharmaceuticals

Healthcare

Sparks - Newron Pharmaceuticals

More on this equity
Newron Pharmaceuticals (SIX: NWRN) announces new evenamide patent
Published by Arron Aatkar, PhD

Newron Pharmaceuticals has announced a new composition of matter patent for its lead schizophrenia candidate, evenamide. The patent was issued by the European Patent Office and claims crystalline forms of the drug candidate, processes for its preparation and its uses. The patent should provide protection to 2044.

Evenamide is currently being evaluated in the registrational Phase III ENIGMA programme, which has been designed to enrol at least 1,000 schizophrenia patients. Top-line results are expected in Q426, representing a significant upcoming inflection point for the company.